Omnicell (NASDAQ:OMCL) Updates Q1 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL) updated its first quarter 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 0.150-0.250 for the period, compared to the consensus estimate of 0.210. The company issued revenue guidance of $255.0 million-$265.0 million, compared to the consensus revenue estimate of $260.2 million. Omnicell also updated its FY 2025 guidance to 1.650-1.850 EPS.

Omnicell Trading Up 0.8 %

Shares of OMCL opened at $34.74 on Friday. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $55.75. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The company’s fifty day moving average is $39.16 and its 200 day moving average is $42.64. The stock has a market capitalization of $1.62 billion, a PE ratio of 128.66, a P/E/G ratio of 7.53 and a beta of 0.85.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Sell-side analysts expect that Omnicell will post 1.09 earnings per share for the current fiscal year.

Analyst Ratings Changes

OMCL has been the subject of a number of research reports. Benchmark reaffirmed a “buy” rating and issued a $62.00 price objective on shares of Omnicell in a research note on Tuesday, February 4th. JPMorgan Chase & Co. cut their price objective on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a report on Thursday, March 20th. Wells Fargo & Company dropped their price objective on Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Bank of America reduced their target price on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research note on Monday, January 6th. Finally, StockNews.com cut Omnicell from a “buy” rating to a “hold” rating in a research report on Monday. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, Omnicell has a consensus rating of “Hold” and an average target price of $51.00.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.